en Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer Molecular Immunology & Vaccines Molecular Immunology & Vaccines مقاله کامل Full Length/Original Article <p><strong>Background: </strong>Gastric cancer arises, mainly, on an inflammatory background. <em>Helicobacter pylori </em>neutrophil activating (HP-NAP) protein functions as a potent pro-inflammatory mediator.&nbsp; Similarly, IL-4 plays a critical role in the inflammation pathway, the levels of which are altered by C to T transition at position -590 in its promoter region. Here, we have aimed to assess the risk of gastritis and gastric cancer in the co-presence of these two inflammation modulating mediators. <strong>Methods: </strong>Gastritis (n=58) and gastric cancer (n=31) patients were evaluated and compared with <em>H. pylori</em>-positive asymptomatic controls (n=46), for serum antibodies against recombinant HP-NAP and IL-4 C-590T single nucleotide polymorphism using immunoblotting and PCR-RFLP, respectively. Multivariable logistic regression, adjusting for age, gender and ethnicity, was used for data analysis. <strong>Results: </strong>In terms of susceptibility to gastritis, seropositivity to HP-NAP projected a risk impact of 4.62 fold (OR=4.62, 95% CI=1.50-14.22), which when present in IL-4 -590 T carriers augmented the risk up to 9.7 fold (OR=9.70, 95% CI=2.06-45.69). A similar pattern, but of a stronger magnitude, occurred for the risk of gastric cancer, which was estimated at 9.07 fold (OR=9.07, 95% CI=1.99-42.0) for HP-NAP-seropositive subjects and was drastically amplified (OR=33.64, 95% CI=2.06-548.68), when double-positive (HP-NAP seropositive/IL-4 -590 T carrier) subjects were examined against double negatives (HP-NAP seronegative/IL-4 -590 CC). <strong>Conclusion: </strong>Our preliminary data indicate that serum antibodies against HP-NAP represent a state of risk, which is further exacerbated in IL-4 -590 T carriers. These biomarkers, if validated in larger prospective studies, can be used to screen for gastric cancer susceptibility.</p> Biomarkers, Genetic Polymorphism, Recombinant 321 329 http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-641&slc_lang=en&sid=1 Yeganeh Talebkhan No HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran Mohsen Doozbakhshan No HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran Samaneh Saberi No HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran Maryam Esmaeili No HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran Najmeh Karami No HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran Nazanin Mohajerani No HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran Afshin Abdirad No Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran Mahmoud Eshagh Hosseini No Department of Gastroenterology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran Azin Nahvijou No Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohammad Ali Mohagheghi No Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran Marjan Mohammadi Yes HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran